Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shariq Haider

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
International Journal of Epidemiology|September 30, 2009
Cohort profile: the Canadian HIV-hepatitis C co-infection cohort studyMarina B Klein, Sahar Saeed, Hong Yang, et al.
Emerging Infectious Diseases|January 20, 2012
Intestinal toxemia botulism in 3 adults, Ontario, Canada, 2006-2008Yolanda D Sheppard, Dean Middleton, Yvonne Whitfield, et al.
Plos One|September 27, 2013
Epidemiology and outcome of pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA) in Canadian hospitalsManal Tadros, Victoria Williams, Brenda L Coleman, et al.
Lancet (London, England)|February 7, 2021
Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trialJohan A Maertens, Galia Rahav, Dong-Gun Lee, et al.
BMJ Open|December 14, 2021
Functional recovery following hospitalisation of patients diagnosed with COVID-19: a protocol for a longitudinal cohort studyJulie C Reid, Andrew P Costa, MyLinh Duong, et al.
The Journal of Antimicrobial Chemotherapy|October 14, 2017
Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal diseaseOliver A Cornely, Michael N Robertson, Shariq Haider, et al.
The Journal of Antimicrobial Chemotherapy|September 30, 2017
Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal diseaseOliver A Cornely, Michael N Robertson, Shariq Haider, et al.
The New England Journal of Medicine|December 7, 2017
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell TransplantationFrancisco M Marty, Per Ljungman, Roy F Chemaly, et al.
Journal of Hepatology|June 14, 2019
Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysisSergio M Borgia, Janet Dearden, Eric M Yoshida, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 25, 2015
Progression of Liver Fibrosis and Modern Combination Antiretroviral Therapy Regimens in HIV-Hepatitis C-Coinfected PersonsLaurence Brunet, Erica E M Moodie, Jim Young, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
International Journal of Epidemiology|September 30, 2009
Cohort profile: the Canadian HIV-hepatitis C co-infection cohort studyMarina B Klein, Sahar Saeed, Hong Yang, et al.
Emerging Infectious Diseases|January 20, 2012
Intestinal toxemia botulism in 3 adults, Ontario, Canada, 2006-2008Yolanda D Sheppard, Dean Middleton, Yvonne Whitfield, et al.
Plos One|September 27, 2013
Epidemiology and outcome of pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA) in Canadian hospitalsManal Tadros, Victoria Williams, Brenda L Coleman, et al.
Lancet (London, England)|February 7, 2021
Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trialJohan A Maertens, Galia Rahav, Dong-Gun Lee, et al.
BMJ Open|December 14, 2021
Functional recovery following hospitalisation of patients diagnosed with COVID-19: a protocol for a longitudinal cohort studyJulie C Reid, Andrew P Costa, MyLinh Duong, et al.
The Journal of Antimicrobial Chemotherapy|October 14, 2017
Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal diseaseOliver A Cornely, Michael N Robertson, Shariq Haider, et al.
The Journal of Antimicrobial Chemotherapy|September 30, 2017
Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal diseaseOliver A Cornely, Michael N Robertson, Shariq Haider, et al.
The New England Journal of Medicine|December 7, 2017
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell TransplantationFrancisco M Marty, Per Ljungman, Roy F Chemaly, et al.
Journal of Hepatology|June 14, 2019
Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysisSergio M Borgia, Janet Dearden, Eric M Yoshida, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 25, 2015
Progression of Liver Fibrosis and Modern Combination Antiretroviral Therapy Regimens in HIV-Hepatitis C-Coinfected PersonsLaurence Brunet, Erica E M Moodie, Jim Young, et al.
Pageof 6